Ex Vivo Protein Binding in Healthy Donors and Diseased Patients, and Comparison of Ex Vivo and In Vitro Results - November, 2013

Plasma protein binding is one of the ADME properties of drug candidates characterized during the drug discovery and development process. The protein binding data are generally derived from in vitro experiments during preclinical development and not until Phase II/III clinical trials are ex vivo data generated when the effects of disease state on pharmacokinetics are investigated.

A recent poster communication by QPS at the 10th International ISSX ( Meeting in Toronto, Canada demonstrated that the effect of disease state on pharmacokinetics is compound dependent. Matching healthy normal control in the same study is therefore necessary for an appropriate comparison of plasma protein binding change due to disease state.

To view the full poster communication, please navigate to: 

20 years in pharma R&D navigation